SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy

Temozolomide (TMZ) is the primary chemotherapeutic drug for treating glioblastoma (GBM); however, the final clinical outcome is considerably limited by the poor response and resistance to TMZ. Although autophagy is thought to be associated with chemotherapy resistance and cancer cell survival, the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jie, Han, Lin, Yang, Feng, Zhao, Mingliang, Zhou, Hong, Hu, Linwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342142/
https://www.ncbi.nlm.nih.gov/pubmed/35730472
http://dx.doi.org/10.1080/21655979.2022.2081463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342142/
https://www.ncbi.nlm.nih.gov/pubmed/35730472
http://dx.doi.org/10.1080/21655979.2022.2081463

Ejemplares similares